On Monday, Shares of Seagate Technology PLC (NASDAQ:STX), added 0.21% and closed at $37.97 in the last trading session. The last trading range of the stock ranges between $37.66 and $38.56. The company’s Market capitalization is $11.41 Billion with the total Outstanding Shares of 298.61 million. Dingley Press, one of the world’s leading catalog printers and distributors, is growing its business by reducing its financial risks and improving operational efficiencies using storage solutions by Reduxio Systems and implementation partner Northern Data Solutions.
Based in Maine, Dingley Press specializes in high-quality catalog printing for companies and started out as L.L. Bean’s in-house printing operation. Since then, Dingley Press has expanded operations with customers in more than 40 states nationwide. In order to meet weekly mailings deadlines to more than 15 million U.S. addresses, Dingley Press relies on its IT infrastructure to operate around the clock.
In the event of an outage during print production, every minute counts. Each hour is valued at hundreds of thousands of dollars. For this reason, Northern Data Solutions recommended the Reduxio HX550 ™ multi-tier system with Reduxio’s BackDating ™ in order to recover data instantaneously, limiting lost productivity from 30 minutes to as little as two minutes.
“The most critical part of Dingley’s business is print production,” said Dingley Press Systems Manager Michael Martell. “An outage can have a domino effect where a missed printing target can require a replan of the entire week’s production processes from print through mailing. To meet business growth demands, we are optimizing our storage solutions, in order to reduce downtime while simultaneously managing our IT costs. Reduxio and Northern Data Solutions assisted us vastly improve the performance and reliability of our existing solutions right away, minimizing down time while limiting our potential financial losses and lost productivity.”
Diamondback Energy Inc (NASDAQ:FANG), jumped 11.10% and closed at $105.21 in the last trading session. The last trading range of the stock ranges between $99.04 and $106.03. The company’s Market capitalization is $8.18 Billion with the total Outstanding Shares of 78.03 million. During the 52-week trading session the minimum price at which share price traded, registered at $55.48 and reached to max level of $106.03. Diamondback Energy, Inc. (FANG) (“Diamondback” or the “Company”) recently offered an operational update for the quarter ended September 30, 2016, raised 2016 production outlook and introduced preliminary guidance for the full year of 2017.
“Diamondback’s continued strong well performance and raised completion cadence during the third quarter reflects our ability to turn our growth engine back on into a rising commodity price after reducing completion activity in early 2016. We are now operating four rigs with a fifth rig to be added in the coming weeks and a sixth rig to be added early next year,” stated Travis Stice, Chief Executive Officer of Diamondback.
Mr. Stice continued, “We have raised 2016 production guidance and introduced 2017 production guidance which shows production growth of more than 30% at the midpoint contrast to updated 2016 expectations. Our existing asset base allows us to drive production growth within cash flow into 2017 and beyond at the current forward strip prices. The ability to drive multi-year organic growth, within cash flow on our existing asset base represents the standard we have always sought to achieve. We believe we are ideally positioned to pursue additional transactions offered they drive exceptional shareholder value while maintaining our disciplined approach to acquisitions. As has been rumored, we were engaged in negotiations involving an acquisition but are not actively pursuing further negotiations at this time.”
On the otherhand Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), jumped 1.06% and closed at $4.75 in the last trading session. The last trading range of the stock ranges between $4.43 and $5.09. The company’s Market capitalization is $165.85 million with the total Outstanding Shares of 35.29 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.42 and reached to max level of $5.69. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, recently declared 24-week data in all 10 patients from the AURION study, an open-label exploratory study to assess the short-term predictors of response using voclosporin (23.7mg BID) in combination with mycophenolate mofetil (MMF) and oral corticosteroids in patients with active lupus nephritis (LN). The data are being presented by Robert Huizinga, Vice President of Clinical Affairs at Aurinia at the 10th Annual European Lupus Meeting in Venice, Italy.
The primary objective of the study is to examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks.
In this study, 70% (7/10) patients achieved complete remission (CR) at 24 weeks as measured by a urinary protein creatinine ratio (UPCR) of ≤ 0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of <5mg/day. Of the 10 patients that achieved a reduction of UPCR of ≥ 25% at 8 weeks, 80% were responders (≥ 50% reduction in UPCR over baseline) at 24 weeks and 70% were in CR at 24 weeks. In addition, inflammatory markers such as C3, C4 and anti-dsDNA all continued to normalize to 24 weeks. Voclosporin was well-tolerated with no unexpected safety signals observed.